Source: Eur Respir J 2007; 29: 965-968
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Imamura Y., Yanagihara K., Fukuda Y., Kaneko Y., Seki M., Izumikawa K., Miyazaki Y., Hirakata Y., Sawa T., Wiener-Kronish J. P., Kohno S.. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model. Eur Respir J 2007; 29: 965-968

Member's Comments

No comment yet.

Related content which might interest you: Effects of direct lung dosing of Tobramycin in a rat chronic infection model using Pseudomonas aeruginosa RP73 Source: International Congress 2018 – Mechanisms of respiratory infection Year: 2018 Pseudomonas aeruginosa influences the inflammatory response of primary bronchial epithelial cells to rhinovirus infection Source: Virtual Congress 2020 – Advances in cystic fibrosis: from microbiome to MRI Year: 2020 The effect of erythromycin on the chronic lower airway infection by pseudomonas aeruginosa Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Impact of Pseudomonas aeruginosa infection on Na+ transport in airway epithelia Source: Annual Congress 2007 - The impact of viral and bacterial infection on the respiratory epithelium Year: 2007 Evaluating the Leeds criteria for Pseudomonas aeruginosa infection in a cystic fibrosis centre Source: Eur Respir J 2006; 27: 937-943 Year: 2006 Panobacumab, a fully human monoclonal antibody for ventilator associated pneumonia caused by Pseudomonas aeruginosa Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections Year: 2010 The effect of clarithromycin on immunity of mice with chronic respiratory infection caused by P. aeruginosa Source: Annual Congress 2008 - Aetiology of respiratory infections: mycobacteria and fungi Year: 2008 Experimental Pseudomonas aeruginosa pneumonia: evaluation of the associated inflammatory response Source: Eur Respir J 2007; 30: 1167-1172 Year: 2007 Comparison between two protocols of preventing treatment of chronic Pseudomonas aeruginosa (Pa) infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005 Autoimmunity to bactericidal/permeability-increasing protein in bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response Source: Eur Respir J, 53 (2) 1801891; 10.1183/13993003.01891-2018 Year: 2019 In vivo evidence for aspergillus fumigatus and pseudomonas aeruginosa driven th-17 type inflammatory responses in the lungs of CF-patients Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease Year: 2009 PcrV antibody prophylaxis in combination with antibiotic therapy reduces lung injury and improves survival in pseudomonas aeruginosa infected mice Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 The role of the type 3 secretion system effector protein ExoY during pathogenesis of pseudomonas aeruginosa lung infections Source: International Congress 2014 – Pathogenesis and mechanisms of respiratory infections Year: 2014 Human airway epithelial cell response to Pseudomonas aeruginosa virulence factors preceded or not by Staphylococcus aureus Source: Eur Respir J 2006; 28: Suppl. 50, 191s Year: 2006 Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis Source: Eur Respir J 2006; 28: 974-979 Year: 2006 Chronic bronchial infection/colonisation: aetiology and mechanisms Source: Eur Respir Monogr 2013; 60: 34-45 Year: 2013 ExoU-induced procoagulant activity in Pseudomonas aeruginosa-infected airway cells Source: Eur Respir J 2008; 32: 1591-1598 Year: 2008 Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis Source: Eur Respir J 2007; 30: 286-292 Year: 2007 Chronic Pseudomonas aeruginosa lung infection, but not CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021